Literature DB >> 8415405

Phenytoin-lipid conjugates: chemical, plasma esterase-mediated, and pancreatic lipase-mediated hydrolysis in vitro.

G K Scriba1.   

Abstract

Phenytoin-lipid conjugates obtained by covalent binding of hydroxymethylphenytoin to diacylglycerides and to 3-acyloxy-2-acyl-oxymethylpropionic acids formed dispersions with a particle size of 10-200 microns when briefly sonicated in a sodium taurodeoxycholate-containing ethanol-water mixture. In contrast to the corresponding bis-deacyl derivatives, the lipids were not significantly hydrolyzed in aqueous buffers and in plasma. Incubation with pancreatic lipase yielded primarily the bis-deacyl compounds, which are comparable to monoglycerides, and subsequently liberated phenytoin. The glyceride-derived prodrugs were better substrates for the enzyme than the 3-acyloxy-2-acyloxymethyl-propionic acid derivatives. It is concluded that the phenytoin lipid conjugates are hydrolyzed by pancreatic lipase in a similar manner as natural triglycerides.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8415405     DOI: 10.1023/a:1018972419482

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Solubility and ionization characteristics of phenytoin.

Authors:  P A Schwartz; C T Rhodes; J W Cooper
Journal:  J Pharm Sci       Date:  1977-07       Impact factor: 3.534

2.  Biovailability of phenytoin in lipid containing dosage forms in rats.

Authors:  S Chakrabarti; F M Belpaire
Journal:  J Pharm Pharmacol       Date:  1978-05       Impact factor: 3.765

3.  Kinetics of diphenylhydantoin disposition in man.

Authors:  T Suzuki; Y Saito; K Nishihara
Journal:  Chem Pharm Bull (Tokyo)       Date:  1970-02       Impact factor: 1.645

4.  Kinetic studies on pancreatic lipase activity in micellar systems. III. Effect of micellar size.

Authors:  H Nakahara; S Okada; H Ohmori; M Masui
Journal:  Chem Pharm Bull (Tokyo)       Date:  1984-10       Impact factor: 1.645

5.  1,3-dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable antineoplastic agent.

Authors:  A Garzon-Aburbeh; J H Poupaert; M Claesen; P Dumont; G Atassi
Journal:  J Med Chem       Date:  1983-08       Impact factor: 7.446

6.  Hydrolysis of fatty acid esters of acetaminophen in buffered pancreatic lipase systmes I.

Authors:  C T Bauguess; F Sadik; J H Fincher; C W Hartman
Journal:  J Pharm Sci       Date:  1975-01       Impact factor: 3.534

7.  Specificity of esterases and structure of prodrug esters: reactivity of various acylated acetaminophen compounds and acetylaminobenzoated compounds.

Authors:  H Seki; T Kawaguchi; T Higuchi
Journal:  J Pharm Sci       Date:  1988-10       Impact factor: 3.534

8.  Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs.

Authors:  Y Yamaoka; R D Roberts; V J Stella
Journal:  J Pharm Sci       Date:  1983-04       Impact factor: 3.534

9.  Phase behaviour of a diglyceride prodrug: spontaneous formation of unilamellar vesicles.

Authors:  S Mantelli; P Speiser; H Hauser
Journal:  Chem Phys Lipids       Date:  1985-08-15       Impact factor: 3.329

10.  Pancreatic lipase-catalyzed hydrolysis of esters of hydroxymethyl phenytoin dissolved in various metabolizable vehicles, dispersed in micellar systems, and in aqueous suspensions.

Authors:  F J Alvarez; V J Stella
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

View more
  2 in total

Review 1.  Critical factors influencing the in vivo performance of long-acting lipophilic solutions--impact on in vitro release method design.

Authors:  Susan Weng Larsen; Claus Larsen
Journal:  AAPS J       Date:  2009-11-06       Impact factor: 4.009

2.  Synthesis and pharmacological properties of 2-[S-acetylthiorphan]-1,3- diacylaminopropan-2-ol derivatives as chimeric lipid drug carriers containing an enkephalinase inhibitor.

Authors:  D M Lambert; F Mergen; C F Berens; J H Poupaert; P Dumont
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.